A Natural Dietary Flavone Myricetin as an α-Hemolysin Inhibitor for Controlling Staphylococcus aureus Infection

Tingting Wang,Peng Zhang,Hongfa Lv,Xuming Deng,Jianfeng Wang

DOI: https://doi.org/10.3389/fcimb.2020.00330

IF: 6.073

2020-07-23

Frontiers in Cellular and Infection Microbiology

Abstract:<span><i>Staphylococcus aureus</i>, an important agent for lethal bacterial infections, can cause a broad spectrum of diseases in various host species. The emergence of multidrug-resistant and highly virulent strains has raised increasing concerns about the novel therapeutic strategies or agents available for treating <i>S. aureus</i> infection. The critical role of Hla, an essential virulence determinant, in the pathogenicity of <i>S. aureus</i> renders this toxin an attractive target for effective therapeutic applications. Here, we have identified myricetin as an effective inhibitor of Hla that simultaneously inhibits Hla production and neutralizes Hla activity without affecting bacterial growth. Myricetin treatment reduced the oligomerization of Hla and Hla-mediated biofilm formation. The addition of myricetin to the coinfection system of host cells and <i>S. aureus</i> significantly decreased cell injury and downregulated the inflammatory response in cells. Furthermore, <i>S. aureus</i>-infected mice that received myricetin showed alleviated tissue damage in the lung. Our results indicated that myricetin inhibits <i>S. aureus</i> virulence by targeting Hla and downregulates the inflammatory response in host cells. Overall, in addition to traditional antibiotics with antibacterial activity, myricetin may represent a potential candidate, and strategy for <i>S. aureus</i> infection.</span>

immunology,microbiology

What problem does this paper attempt to address?

The paper mainly addresses the following key issues:

1. **Finding new therapeutic strategies to combat resistant Staphylococcus aureus (S. aureus) infections**: The emergence of multi-drug resistant and highly virulent strains challenges the effectiveness of traditional antibiotics, necessitating the exploration of new therapeutic strategies.

2. **Targeting the key virulence factor α-hemolysin (Hla) of S. aureus as a therapeutic target**: α-hemolysin (Hla) is an important virulence factor in S. aureus that has destructive effects on host cells, making it a potential target for inhibiting S. aureus toxicity.

3. **Identifying the natural flavonoid compound myricetin as an inhibitor of Hla**: The study found that myricetin can effectively inhibit the production and activity of Hla without affecting bacterial growth.

Specifically, the study validated the mechanism of action of myricetin through a series of experiments:
- Myricetin can reduce the oligomerization process of Hla, thereby weakening its ability to form pores in the cell membrane.
- Myricetin reduces Hla-mediated biofilm formation, which may help prevent bacterial colonization and infection spread.
- In vitro cell experiments showed that myricetin significantly reduced cell damage caused by S. aureus.
- Myricetin can also inhibit Hla-triggered immune signaling pathways (such as the MAPK and NF-κB pathways), thereby reducing inflammatory responses.
- In vivo mouse infection models confirmed that myricetin can alleviate lung tissue damage.

In summary, the paper demonstrates through laboratory research that myricetin, as a natural compound, has potential in controlling S. aureus infections, providing a theoretical basis for the development of new anti-infection strategies.